4.4 Article

Predictors of Cardiac Perforation With Catheter Ablation of Atrial Fibrillation

Journal

JACC-CLINICAL ELECTROPHYSIOLOGY
Volume 6, Issue 6, Pages 636-645

Publisher

ELSEVIER
DOI: 10.1016/j.jacep.2020.01.011

Keywords

ablation; atrial fibrillation; cardiac tamponade; intracardiac echocardiography

Funding

  1. Johnson and Johnson
  2. Boston Scientific
  3. Biosense Webster
  4. Abbott
  5. Medtronic
  6. Biotronik
  7. Bristol-Myers Squibb
  8. Pfizer
  9. Janssen Pharmaceuticals
  10. Food and Drug Administration
  11. Gilead
  12. Philips
  13. Portola
  14. Zoll
  15. Medpace
  16. American College of Cardiology
  17. American Heart Association
  18. National Heart, Lung, and Blood Institute

Ask authors/readers for more resources

OBJECTIVES This study identified factors associated with risk for cardiac perforation in the setting of atrial fibrillation (AF) ablation in contemporary clinical practice. BACKGROUND Cardiac perforation is an uncommon but potentially fatal complication of AF ablation. An improved understanding of factors associated with cardiac perforation could facilitate improvements in procedural safety. METHODS Logistic regression models were used to assess predictors of cardiac perforation among Medicare beneficiaries who underwent AF ablation from July 1, 2013 and December 31, 2017. Cardiac perforation was defined as a diagnosis of hemopericardium, cardiac tamponade, or pericardiocentesis, within 30 days of AF ablation. RESULTS Of 102,398 patients who underwent AF ablation, 0.61% (n = 623) experienced cardiac perforation as a procedural complication. Rates of cardiac perforation decreased over time. In adjusted analyses of the overall population, female sex (odds ratio [On 1.34; 95% confidence interval [CI]: 1.14 to 1.58; p 0.0004), obesity (OR: 1.35; 95% CI: 1.09 to 1.68; p 0.0050), and absence of intracardiac echocardiography (ICE) (OR: 4.85; 95% CI: 4.11 to 5.71; p < 0.0001) were associated with increased risk for cardiac perforation, whereas previous cardiac surgery (OR: 014; 95% 0: 0.07 to 0.26; p < 0.0001) was associated with a tower risk for perforation. Patient risk factors for cardiac perforation were identical in the subset of patients in whom ICE was used (n 76,134). A risk score was generated with the following point assignments: female sex (1 point); obesity (1 point); nonuse of ICE (5 points); and previous cardiac surgery (-6 points). CONCLUSIONS Cardiac perforation is a rare complication of AF ablation; incidence has decreased over time. One of the strongest predictors of cardiac perforation in the contemporary era is a modifiable factor, use of intraprocedurat ICE. (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available